GlucoTrack: Below) To Reflect The Terms Of The Exchange Agreement, Which Supersedes And Replaces In Its Entirety The Exchange Agreement Dated July 22, 2026 (the “original Exchange Agreement”) Previously Filed As Exhibit 10.1 To The Original Report, And (ii) File The Exchange Agreement As Exhibit 10.1 To This Amendment. This Amendment Amends And Restates The Original Report In Its Entirety, And The Original Exchange Agreement Is Hereby Superseded And Replaced In Its Entirety By The Exchange Agreement Attached As Exhibit 10.1 To This Amendment, Creation Of A Direct Financial Obligation Or An Obligation Under An Offbalance Sheet Arrangement Of A Registrant, Unregistered Sales Of Equity Securities, Financial Statements And Exhibits

Item 1.01 below) to reflect the terms of the Exchange Agreement, which supersedes and replaces in its entirety the exchange agreement dated July 22, 2026 (the “Original Exchange Agreement”) previously filed as Exhibit 10.1 to the Original Report, and (ii) file the Exchange Agreement as Exhibit 10.1 to this Amendment. This Amendment amends and restates the Original Report in its entirety, and the Original Exchange Agreement is hereby superseded and replaced in its entirety by the Exchange Agreement attached as Exhibit 10.1 to this Amendment. Item 1.01. Entry Into a Material Definitive Agreement. On July 24, 2026, the Company entered into an Exchange Agreement (the “Exchange Agreement”) with an investor (the “Investor”) relating to an existing promissory note previously issued to the Investor on September 12, 2025, in the original principal amount of $3,600,000, with such principal subsequently reduced by $600,000 pursuant to that certain exchange agreement, dated April 13, 2026, by and between the Company and the Investor (the “First Exchange Agreement”), and further reduced by $988,000 pursuant to that certain exchange agreement, dated April 29, 2026, by and between the Company and the Investor (the “Second Exchange Agreement”) (as modified, the “Original Note”). The Exchange Agreement supersedes and replaces in its entirety the Original Exchange Agreement. Pursuant to the Exchange Agreement, the Company and the Investor partitioned a new promissory note in the original principal amount of $900,000 (the “Partitioned Note”) from the Original Note. Following such partition, the outstanding balance of the Original Note was reduced by an amount equal to the initial outstanding balance of the Partitioned Note, and the Original Note otherwise remains in full force and effect in accordance with its terms. Under the Exchange Agreement, the Company and the Investor further agreed that the Investor may, from time to time, exchange all or any portion of the Partitioned Note for shares of the Company’s common stock, par value $0.001 per share (the “Exchange Shares”). The number of Exchange Shares issuable in connection with the exchange is calculated by dividing the original principal amount of the Partitioned Note by the “Minimum Price,” which is equal to the lower of (A) the Nasdaq Official Closing Price of the common stock immediately preceding the execution of the Exchange Agreement, or (B) the arithmetic average of the five Nasdaq Official Closing Prices for the common stock immediately preceding the execution of the Exchange Agreement. Pursuant to the Exchange Agreement, the Exchange Shares shall be delivered to the Investor on or before August 31, 2026. Each exchange consists solely of the surrender and cancellation of the applicable portion of the Partitioned Note in exchange for the issuance of the Exchange Shares, with no cash or other consideration paid by the Investor. The issuance of the Exchange Shares is subject to a beneficial ownership limitation, which generally restricts the Company from issuing shares to the Investor to the extent that such issuance would cause the Investor and its affiliates to beneficially own more than 9.99% of the Company’s outstanding common stock, calculated in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended. To the extent the limitation applies, the Exchange Shares may be issued in one or more tranches, and any portion of the Partitioned Note not exchanged as a result of the limitation will remain outstanding and exchangeable in accordance with the terms of the Exchange Agreement. The Partitioned Note was issued in a private placement to the Investor pursuant to an exemption for transactions by an issuer not involving a public offering under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The Exchange Shares are being issued pursuant to the exemption from the registration requirements of the Securities Act provided by Section 3(a)(9) of the Securities Act, on the basis that (a) the Exchange Shares will be issued in exchange for other outstanding securities of the Company; (b) there will be no additional consideration delivered by the Investor in connection with the exchange; and (c) there will be no commissions or other remuneration paid by the Company in connection with the exchange. The foregoing description of the Exchange Agreement does not purport to be complete and is qualified in its entirety by reference to the Exchange Agreement, a form which is filed herewith as Exhibit 10.1, and incorporated herein by reference. Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. To the extent required by Item 2.03 of Form 8-K, the information contained in Item 1.01 is hereby incorporated by reference into this Item 2.03 in its entirety. Item 3.02. Unregistered Sales of Equity Securities To the extent required by Item 3.02 of Form 8-K, the information contained in Item 1.01 is hereby incorporated by reference into this Item 3.02 in its entirety. Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 10.1 Form of Exchange Agreement, dated July 24, 2026 104 Cover Page Interactive Data File (embedded within the inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 29, 2026 GLUCOTRACK, INC. By: /s/ Erik Emerson Name: Erik Emerson Title: Chief Executive Officer

Prova di 7-giorni Accesso demo

Prova di 7-giorni Accesso demo

Ottieni l'accesso al più grande database finanziario

Prova di 7-giorni Accesso demo

Ottieni l'accesso al più grande database finanziario

Rappresentanti aziendali 7 giorni di prova GRATUITA

Investitore privato

Altre notizie

7-giorni Accesso di prova

Perché Cbonds?